Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s11136-011-9902-y) contains supplementary material, which is available to authorized users.
To review published studies on the effect of diabetes and its complications on utility scores to establish whether there is systematic variation across studies and to examine the implications for the estimation of quality-adjusted life years (QALYs).
A systematic review was performed using studies reporting QALY measures elicited from people with diabetes including those with a history of complications. Meta-analysis was used to obtain the average utility, and meta-regression was employed to examine the impact of study characteristics and elicitation methods on these values. The effect of different utility scores on QALYs was examined using diabetes simulation models.
In the meta-analysis based on 45 studies reporting 66 values, the average utility score was 0.76 (95% CI 0.75–0.77). A meta-regression showed significant variation due to age, method of elicitation and the proportion of males. The average utility score for individual complications ranged from 0.48 (95% CI 0.25, 0.71) for chronic renal disease to 0.75 (95% CI 0.73, 0.78) for myocardial infarction, and these differences produced meaningful changes in simulated QALYs. There was significant heterogeneity between studies.
We provide summary utility scores for diabetes and its major complications that could help inform economic evaluation and policy analysis.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Supplementary material 1 (DOC 223 kb)11136_2011_9902_MOESM1_ESM.doc
Palmer, A. J., Roze, S., Valentine, W. J., et al. (2004). The CORE diabetes model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Type 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion,20(Suppl), S5–S26. PubMedCrossRef
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., et al. (2005). Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine,142(5), 323–332. PubMed
EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy,16(3), 199–208. CrossRef
Sterne, J. A. C., Bradburn M. J., & Egger M. (2001) Meta-analysis in Stata. (Chapter 18) Resource document. Blackwell Publishing.
Hedges, L. V., Tipton, E., & Johnson, M. C. (2010). Robust variance estimation in meta-regression with dependent effect size estimates. Research Synthesis Methods,1(1), 39–65. CrossRef
Boye, K. S., Matza, L. S., Oglyesby, A., Malley, K., Kim, S., Hayes, R. P. & Brodows, R. (2006). Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health and Quality of Life Outcomes, October 4, 80.
Farmer, A. J., Wade, A. N., French, D. P., Simon, J., Yudkin, P., Gray, A., et al. (2009). Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technology Assessment,13(15), 1–50.
Sakthong, P., Charoenvisuthiwongs, R., & Shabunthom, R. (2008). A comparison of EQ-5D index scores using the UK, US and Japan preference weights in a Thai sample with type 2 diabetes. Health and quality of life outcomes,23(6), 71. CrossRef
ADVANCE Collaborative Group. (2007). Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet,370, 829–840. CrossRef
Levy, A. R., Christensen, T. L., & Johnson, J. A. (2008). Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health and Quality of Life Outcomes,29(6), 73. CrossRef
Brown, M. M., Brown, G. C., Sharma, S., Landy, J., & Bakal, J. (2002). Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Archives of Ophthalmology,120(4), 481–484. PubMed
Clarke, P., Gray, A., & Holman, R. (2002). Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Medical Decision Making,22(4), 340–349. PubMed
Wee, H. L., Cheung, Y. B., Li, S. C., Fong, K. Y., & Thumboo, J. (2005). The impact of diabetes mellitus and other chronic medical conditions on health-related quality of life: Is the whole greater than the sum of its parts? Health and Quality of Life Outcomes January,3, 2. CrossRef
Supina, A. L., Feeny, D. H., Carroll, L. J., & Johnson, J. A. (2006). Misinterpretation with norm-based scoring of health status in adults with type 1 diabetes. Health and Quality of Life Outcomes,16(4), 15. CrossRef
Boye, K. S., Yurgin, N., Dilla, T., Cordero, L. A., Badia, X., Suriñach, N. L., et al. (2007). Health-related quality of life of patients with type 2 diabetes mellitus in primary care in Spain: self-reported and proxy assessment using the EQ-5D. Journal of Medical Economics,10(1), 41–58. CrossRef
Glasziou, P., Alexander, J., Beller, E., Clarke, P. M., & The ADVANCE Collaborative Group. (2007). Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health and Quality of Life Outcomes,27(5), 21. CrossRef
Arne, M., Janson, C., Janson, S., Boman, G., Lindqvist, U., Berne, C., et al. (2009). Physical activity and quality of life in subjects with chronic disease: Chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. Scandinavian Journal of Primary Health Care,27(3), 141–147. PubMedCrossRef
Zhang, X. H., Wee, H. L., Tan, K., Thumboo, J., & Li, S. C. (2009). Is diabetes knowledge associated with health-related quality of life among subjects with diabetes? A preliminary cross-sectional convenience-sampling survey study among English-speaking diabetic subjects in Singapore. Journal of Chinese Clinical medicine,4(3), 144–150.
Imayama, I. (2009). Determinants of quality of life in adults with diabetes. Centre of Health Promotion Studies, School of Public Health. US: DPhil University of Alberta.
Kind, P., Hardman, G. & Macran Susan. (1999) UK population norms for EQ-5D: Discussion Paper 172 The University of York, Centre for Health Economics.
Ariza-Ariza, R., Hernandez-Cruz, B., Carmona, L., Ruiz-Montesinos, M. D., Ballina, J., Navarro-Sarabia, F., et al. (2006). Assessing utility values in rheumatoid arthritis: A comparison between time trade off and the EuroQol. Arthritis Care & Research,55(5), 751–756. CrossRef
Ramon Luengo-Fernandez. (2009). Resource costs, health outcomes and cost effectiveness in stroke care: Evidence from the Oxford Vascular Study. DPhil, Oxford University, UK.
National Institute for Clinical Excellence (NICE) (2004), Guide to the methods of technology appraisal, NICE, London.
Commonwealth of Australia. (1995). Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including economic analysis. Canberra: Department of Health and Community Services.
- A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation
Tom W. C. Lung
Alison J. Hayes
Philip M. Clarke
- Springer Netherlands